What is PT-141 and what has it been approved for?

PT-141, or bremelanotide, is a synthetic peptide that acts as a melanocortin-receptor agonist in the central nervous system, on circuits linked to sexual desire. Under the name Vyleesi it is approved by the U.S. FDA (since 2019) for hypoactive sexual desire disorder in premenopausal women, by prescription. Any other use is off-label and supported by much less evidence. This guide is educational, not medical advice.

How does it differ from Viagra?

In the mechanism. Viagra (sildenafil) and other PDE5 inhibitors act vascularly, facilitating genital blood flow; PT-141 acts centrally, on the brain circuits of desire. They do not address the same thing and are not interchangeable. This is not medical advice: any decision about sexual health should be discussed with a healthcare professional.

Is approved Vyleesi the same as 'research-grade' material?

No. Vyleesi is an approved prescription medicine, manufactured and controlled as a regulated pharmaceutical product. Material sold as 'research grade' outside pharmacy channels is not the same product: it lacks clinical oversight, dose control and quality assurance, and is not intended for human use. A third-party CoA is the minimum verification of any material, but it does not replace a prescriber's evaluation.

← Guides

PT-141 (Bremelanotide): what it is and what is being researched

PT-141, also known as bremelanotide, is one of the peptides that raises the most questions for people beginning to study sexual health, partly because — unlike most molecules in this field — it does have a version approved as a medicine. This guide explains, at an educational level, what the molecule is, how it acts, what has been researched and approved, how it differs from drugs like Viagra, and which adverse effects have been described. It is not medical advice or a recommendation for use, and it contains no doses or protocols. Sexual health is a sensitive matter best handled with a professional: if you are considering anything related to your own health, speak with your doctor first.

What PT-141 (bremelanotide) is

PT-141 is the name popularly used for bremelanotide, a synthetic peptide. Its origin is curious: it comes out of research on melanotan II, a molecule studied for its effect on skin pigmentation, in which an increase in sexual desire and arousal was noted as a side effect. From there, bremelanotide was developed as a melanocortin-receptor agonist. In plain terms, an 'agonist' is a molecule that activates a specific receptor, mimicking the signal a natural body substance would trigger. Bremelanotide acts mainly on the MC4R receptor (with some MC3R activity), receptors found in the central nervous system. The campus PT-141 profile lists its full name, synonyms and reference details.

How it acts: in the brain, not the blood vessels

What sets PT-141 apart is where and how it acts. Rather than working on genital blood flow, bremelanotide activates central nervous system circuits linked to sexual desire and arousal. In other words, it is described as a 'central' mechanism — acting in the brain — rather than a 'peripheral' or vascular one. This difference is the key to understanding why it has been studied in the context of low sexual desire, not just physical response. It is worth stressing that, even though the mechanism is well described, understanding how a molecule acts does not mean one can precisely predict its effects or safety in any given person; that is the job of clinical evaluation and trials.

What has been researched and approved

Bremelanotide is one of the few peptides in this space with genuine human regulatory approval. Under the brand name Vyleesi, it was approved by the U.S. FDA in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women. That approval was based on the RECONNECT program: two large randomized, placebo-controlled Phase 3 trials. It is important to grasp the scope of that approval: it is a specific, narrow indication (one particular population and condition), by prescription. Use outside that population — for example in men, or as a general arousal enhancer — is 'off-label' and supported by much thinner evidence. It has also been investigated as a possible centrally-acting alternative or adjunct to vascular approaches for erectile dysfunction, but that belongs to the realm of research, not approved use.

Difference from Viagra, and adverse effects

The most common comparison is with Viagra (sildenafil) and other PDE5 inhibitors. The fundamental difference is the mechanism: PDE5 inhibitors act vascularly, facilitating blood flow in response to existing arousal; PT-141 acts centrally, on the brain circuits of desire. They are not interchangeable and do not address the same thing. As for adverse effects, the most common in trials were nausea and flushing; headache and transient increases in blood pressure were also reported, which is why the prescribing information advises caution in people with cardiovascular risk factors. In addition, the molecule can cause changes in skin pigmentation, an effect tied to its action on melanocortin receptors. All of this reinforces why the approved version is dispensed by prescription and under medical supervision.

Frequently asked questions

What is PT-141 and what has it been approved for?: PT-141, or bremelanotide, is a synthetic peptide that acts as a melanocortin-receptor agonist in the central nervous system, on circuits linked to sexual desire. Under the name Vyleesi it is approved by the U.S. FDA (since 2019) for hypoactive sexual desire disorder in premenopausal women, by prescription. Any other use is off-label and supported by much less evidence. This guide is educational, not medical advice.
How does it differ from Viagra?: In the mechanism. Viagra (sildenafil) and other PDE5 inhibitors act vascularly, facilitating genital blood flow; PT-141 acts centrally, on the brain circuits of desire. They do not address the same thing and are not interchangeable. This is not medical advice: any decision about sexual health should be discussed with a healthcare professional.
Is approved Vyleesi the same as 'research-grade' material?: No. Vyleesi is an approved prescription medicine, manufactured and controlled as a regulated pharmaceutical product. Material sold as 'research grade' outside pharmacy channels is not the same product: it lacks clinical oversight, dose control and quality assurance, and is not intended for human use. A third-party CoA is the minimum verification of any material, but it does not replace a prescriber's evaluation.

✓ Last reviewed · 2026-07-24